AT1 14.3% 2.4¢ atomo diagnostics limited

Ann: Atomo & Access Bio enter North American COVID-19 partnership, page-134

  1. 1,209 Posts.
    lightbulb Created with Sketch. 646
    Yes and no. Both have a place and enormous potential still to go.

    Antigen tests are best performed in labs to reduce false positives (for now). There are 'rapid' antigen tests with faster response times but the accuracy rate is still not anywhere past 90% reliably enough - still evolving. And none produced with a 100% accuracy test strip yet for portable device....but no doubt in the works.

    Antibodies lab + rapid device tests have already achieved 100% accuracy potential (if there are enough antibodies in the host).

    For post-vaccine tests, antibodies are best to check its working..possibly repeatedly to ensure immunity remains.

    until a successful vaccine & reaches majority globally (ie: years for >90% like polio, TB etc), pretty much every test type is neccessary considering the global demand for constant testing - whether lab or portable.
 
watchlist Created with Sketch. Add AT1 (ASX) to my watchlist
(20min delay)
Last
2.4¢
Change
0.003(14.3%)
Mkt cap ! $15.34M
Open High Low Value Volume
2.1¢ 2.4¢ 2.1¢ $13.07K 607.5K

Buyers (Bids)

No. Vol. Price($)
1 405 2.3¢
 

Sellers (Offers)

Price($) Vol. No.
2.4¢ 277040 4
View Market Depth
Last trade - 16.10pm 15/08/2024 (20 minute delay) ?
AT1 (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.